Exclusive worldwide cooperation in next generation sequencing solutions
We offer in cooperation with Genomatix Software GmbH, a leading company in complex analysis and interpretation of next generation sequencing data, state-of-the art solutions for comprehensive genome analysis and re-sequencing project services.
Sophisticated next generation sequencing services:
- Experimental planning and consulting
- Wet-lab work and data analysis
- Data interpretation
- Deep biological understanding
Benefit from a high level of expertise in understanding and the interpretation of complex biological processes.
With Genomatix we offer powerful turnkey solutions downstream of next generation sequencing combined with highest scientific standards and cutting edge technology:
- Extraction of the relevant biological knowledge from ChIP-Seq and DGE studies
- Correlation and visualisation of next generation sequencing results with an extended genome annotation
We are able to deliver ultra-fast mapping of sequence reads of any length above nine base pairs. Ten million typical next generation sequencing reads of variable lengths can be perfectly and uniquely mapped to the human genome. The solution is flexible and allows analysis of any number of indels and point mutations, delivering a uniqueness measure for each mapped read. Cutting edge technology identifies splice junction tags for advanced transcriptome analysis.
Take advantage of a complete solution for ChiP-seq and transcriptome analysis downstream of mapping next generation sequencing reads to the genome. Annotation data complement the results from a next generation sequencing project and expand it by integrating each new sequencing run to a customised genome database.
We can generate and analyse data from next generation sequencing systems such as Illumina’s Genome Analyzer and the Genome Sequencer™ FLX.
Applicative know-how and powerful bioinformatic capabilities are the key for effective project consulting and execution. This has already been demonstrated in several large projects executed by Eurofins MWG Operon’s and Genomatix’ joint efforts.
